Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: RIGEL PHARMACEUTICALS INC
Awarding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Funding agency: Department of Health and Human Services / Office of Assistant Secretary for Preparedness and Response
Period of performance: 2023-05-01 to 2025-10-31
Current total value of award: $749999
Description: RIGEL PHARMACEUTICALS: THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO EVALUATE THE IMPACT OF FOSTAMATINIB TREATMENT DURING HOSPITALIZATION RESULTING FROM ARDS ON LONG-TERM OUTCOMES INCLUDING CLINICAL, BIOMARKER, IMAGING, QOL, FUNCTIONAL AND LUNG FUNCTI